MelanomaPhase 3COMBI-iNCT02967692
A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma
A Phase 3 study testing Spartalizumab, Dabrafenib and Trametinib in people with Melanoma, run by Novartis Pharmaceuticals at 179 sites in 29 countries.
Trial summary
The purpose of this study was to evaluate safety and efficacy of the combination of an anti-PD-1 antibody (PDR001), a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in patients with BRAF V600 mutant, unresectable and metastatic melanoma. Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- Melanoma
- What is being tested?
- Spartalizumab, Dabrafenib and Trametinib
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 568 participants
- Where
- 179 sitesin 29 countries
- Study dates
- 17 Feb 2017to 21 Aug 2024
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Histologically confirmed, unresectable or metastatic melanoma with BRAF V600 mutation
- Aspartate transaminase (AST) < 2.5× ULN and Alanine transaminase (ALT) < 2.5× ULN
- Measurable disease according to RECIST 1.1
- ECOG performance status ≤ 1
- Part 2: Biomarker cohort
- Histologically confirmed, unresectable or metastatic melanoma with BRAF V600 mutation
Show all 13Show fewer
- At least two cutaneous or subcutaneous or nodal lesions for tumor sample collection
- Measurable disease according to RECIST 1.1
- ECOG performance status ≤ 2
- Part 3: Double-blind, randomized, placebo-controlled part
- Histologically confirmed, unresectable or metastatic melanoma with BRAF V600 mutation
- ECOG performance status ≤ 2
- Measurable disease according to RECIST 1.1
Who cannot join
- Part 1: Safety run-in
- Subjects with uveal or mucosal melanoma
- Any history of CNS metastases
- Prior systemic anti-cancer treatment for unresectable or metastatic melanoma
- Neoadjuvant and/or adjuvant therapy for melanoma completed less than 6 months prior to enrollmen
- Radiation therapy within 4 weeks prior to start of study treatment
Show all 15Show fewer
- Active autoimmune disease, and/or history of autoimmune disease(s) that required treatment
- Parts 2 \& 3: Biomarker cohort \& double-blind, randomized, placebo-controlled part
- Subjects with uveal or mucosal melanoma
- Prior systemic anti-cancer treatment for unresectable or metastatic melanoma
- Neoadjuvant and/or adjuvant therapy for melanoma completed less than 6 months prior to enrollment
- Radiation therapy within 4 weeks prior to start of study treatment
- Clinically active cerebral melanoma metastasis.
- Active autoimmune disease, and/or history of autoimmune disease(s) that required treatment
- Other protocol-defined Inclusion/Exclusion may apply.
Trial locations and contacts
179 sites in 29 countries.
179 sites in 29 countries
France26 sites
Novartis Investigative Site
Amiens, 80054
Novartis Investigative Site
Besançon, 25030
Novartis Investigative Site
Bobigny, 93009
Novartis Investigative Site
Bordeaux, 33075
Novartis Investigative Site
Boulogne-Billancourt, 92104
Novartis Investigative Site
Caen, 14033
Novartis Investigative Site
Clermont-Ferrand, 63003
Novartis Investigative Site
Dijon, 21034
Novartis Investigative Site
Grenoble, 38043
Novartis Investigative Site
Le Mans, 72000
Novartis Investigative Site
Lille, 59037
Novartis Investigative Site
Limoges, Haute Vienne, 87000
Novartis Investigative Site
Lorient, 56322
Novartis Investigative Site
Lyon, 69373
Novartis Investigative Site
Marseille, 13885
Novartis Investigative Site
Mulhouse, 68070
Novartis Investigative Site
Nice, 06202
Novartis Investigative Site
Paris, 75475
Novartis Investigative Site
Pierre-Bénite, 69495
Novartis Investigative Site
Poitiers, 86021
Novartis Investigative Site
Reims, 51092
Novartis Investigative Site
Rouen, 76031
Novartis Investigative Site
Strasbourg, 67091
Novartis Investigative Site
Toulouse, 31059
Novartis Investigative Site
Vandœuvre-lès-Nancy, 54519
Novartis Investigative Site
Villejuif, 94800
Germany26 sites
Novartis Investigative Site
Berlin, 13353
Novartis Investigative Site
Berlin, 13578
Novartis Investigative Site
Bonn, 53105
Novartis Investigative Site
Chemnitz, 09117
Novartis Investigative Site
Dresden, 01307
Novartis Investigative Site
Düsseldorf, 40225
Novartis Investigative Site
Erfurt, 99089
Novartis Investigative Site
Essen, 45147
Novartis Investigative Site
Freiburg im Breisgau, 79106
Novartis Investigative Site
Gera, 07548
Novartis Investigative Site
Halle, Saxony-Anhalt, 06120
Novartis Investigative Site
Hamburg, 20246
Novartis Investigative Site
Hanover, 30625
Novartis Investigative Site
Heidelberg, 69120
Novartis Investigative Site
Homburg, 66421
Novartis Investigative Site
Kiel, 24105
Novartis Investigative Site
Leipzig, Saxony, 04103
Novartis Investigative Site
Mainz, 55131
Novartis Investigative Site
Mannheim, Baden-Wurttemberg, 68305
Novartis Investigative Site
Marburg, 35039
Novartis Investigative Site
Minden, 32429
Novartis Investigative Site
München, 81377
Novartis Investigative Site
Münster, 48157
Novartis Investigative Site
Regensburg, Bavaria, 93053
Novartis Investigative Site
Stade, 21682
Novartis Investigative Site
Tübingen, 72076
Italy17 sites
Novartis Investigative Site
Bari, BA, 70124
Novartis Investigative Site
Bergamo, BG, 24127
Novartis Investigative Site
Bologna, BO, 40138
Novartis Investigative Site
Brescia, BS, 25123
Novartis Investigative Site
Candiolo, TO, 10060
Novartis Investigative Site
Genova, GE, 16132
Novartis Investigative Site
Meldola, FC, 47014
Novartis Investigative Site
Milan, MI, 20133
Novartis Investigative Site
Milan, MI, 20141
Novartis Investigative Site
Modena, MO, 41124
Novartis Investigative Site
Monza, MB, 20900
Novartis Investigative Site
Naples, 80131
Novartis Investigative Site
Padova, PD, 35100
Novartis Investigative Site
Roma, RM, 00167
Novartis Investigative Site
Siena, SI, 53100
Novartis Investigative Site
Torino, TO, 10126
Novartis Investigative Site
Verona, VR, 37134
Spain13 sites
Novartis Investigative Site
A Coruña, Galicia, 15006
Novartis Investigative Site
Badalona, Catalonia, 08916
Novartis Investigative Site
Barcelona, Catalonia, 08036
Novartis Investigative Site
Jerez de la Frontera, Cadiz, 11407
Novartis Investigative Site
Las Palmas de Gran Canaria, 35016
Novartis Investigative Site
Madrid, 28009
Novartis Investigative Site
Madrid, 28034
Novartis Investigative Site
Madrid, 28050
Novartis Investigative Site
Madrid, 28222
Novartis Investigative Site
Málaga, Andalusia, 29010
Novartis Investigative Site
Oviedo, Principality of Asturias, 33011
Novartis Investigative Site
Seville, Andalusia, 41009
Novartis Investigative Site
Valencia, Valencia, 46014
United States12 sites
California Cancer Associates for Research and Excellence
Encinitas, California, 92024
Univ of TX MD Anderson Cancer Cntr
Houston, Texas, 77030
University of Tennessee Medical Ctr
Knoxville, Tennessee, 37920
Johns Hopkins U
Lutherville, Maryland, 21093
NYU Laura and Isaac Perlmutter Cancer Center
New York, New York, 10016
Nebraska Cancer Specialists
Omaha, Nebraska, 68130
UC Irvine Medical Center
Orange, California, 92613-4091
University of Pittsburgh Med Center
Pittsburgh, Pennsylvania, 15213
Utah Cancer Specialists
Salt Lake City, Utah, 84106
California Pacific Medical Center
San Francisco, California, 94115
Stanford Cancer Center
Stanford, California, 94305
University of Kansas Cancer Center
Westwood, Kansas, 66205
United Kingdom9 sites
Novartis Investigative Site
Guildford, Surrey, GU2 7XX
Novartis Investigative Site
Leicester, LE1 5WW
Novartis Investigative Site
London, NW3 2QG
Novartis Investigative Site
Manchester, M20 2BX
Novartis Investigative Site
Middlesbrough, TS4 3BW
Novartis Investigative Site
Preston, PR2 9HT
Novartis Investigative Site
Rickmansworth Road, WD187HT
Novartis Investigative Site
Sutton, Surrey, SM2 5PT
Novartis Investigative Site
Truro, Cornwall, TR1 3LJ
Russia8 sites
Novartis Investigative Site
Chelyabinsk, 454048
Novartis Investigative Site
Moscow, 115478
Novartis Investigative Site
Moscow, 143423
Novartis Investigative Site
Nizhny Novgorod, 603137
Novartis Investigative Site
Omsk, 644013
Novartis Investigative Site
Saint Petersburg, 197758
Novartis Investigative Site
Saint Petersburg, 198255
Novartis Investigative Site
Samara, 443011
Czechia7 sites
Novartis Investigative Site
Brno, Czech Republic, 656 53
Novartis Investigative Site
Hradec Králové, CZE, 500 05
Novartis Investigative Site
Olomouc, 779 00
Novartis Investigative Site
Ostrava, Poruba, 708 52
Novartis Investigative Site
Prague, 100 34
Novartis Investigative Site
Prague, 12808
Novartis Investigative Site
Zlín, Czech Republic, 762 75
Australia5 sites
Novartis Investigative Site
Gateshead, New South Wales, 2290
Novartis Investigative Site
Greenslopes, Queensland, 4120
Novartis Investigative Site
Melbourne, Victoria, 3004
Novartis Investigative Site
Nedlands, Western Australia, 6009
Novartis Investigative Site
North Sydney, New South Wales, 2060
Austria5 sites
Novartis Investigative Site
Graz, 8036
Novartis Investigative Site
Innsbruck, Tyrol, 6020
Novartis Investigative Site
Linz, 4020
Novartis Investigative Site
Salzburg, A-5020
Novartis Investigative Site
Sankt Pölten, 3100
Canada5 sites
Novartis Investigative Site
Montreal, Quebec, H3T 1E2
Novartis Investigative Site
Montreal, Quebec, H4A 3J1
Novartis Investigative Site
Sherbrooke, Quebec, J1H 5N4
Novartis Investigative Site
Toronto, Ontario, M4N 3M5
Novartis Investigative Site
Vancouver, British Columbia, V5Z 4E6
Japan5 sites
Tokyo Metropolitan Komagome Hospital
Bunkyo Ku, Tokyo, 113-8677
National Cancer Hospital
Chuo Ku, Tokyo, 104 0045
Kyushu University Hospital
Fukuoka, Fukuoka, 812-8582
Osaka International Cancer Institute
Osaka, Osaka, 541-8567
Kyoto University Hospital
Sakyo Ku, Kyoto, 606 8507
Argentina4 sites
Novartis Investigative Site
Caba, C1431FWO
Novartis Investigative Site
CABA, Buenos Aires, C1125ABD
Novartis Investigative Site
CABA, Buenos Aires, C1426ANZ
Novartis Investigative Site
Rosario, Santa Fe Province, S2000KZE
Brazil4 sites
Novartis Investigative Site
Curitiba, Paraná, 80530 010
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, 90035-003
Novartis Investigative Site
Rio de Janeiro, 20560-120
Novartis Investigative Site
São Paulo, São Paulo, 01246 000
Chile3 sites
Novartis Investigative Site
Santiago, 7500921
Novartis Investigative Site
Santiago, 8420383
Novartis Investigative Site
Temuco, Araucania, 4810469
Hungary3 sites
Novartis Investigative Site
Budapest, H 1122
Novartis Investigative Site
Debrecen, 4032
Novartis Investigative Site
Szeged, H 6725
Israel3 sites
Novartis Investigative Site
Haifa, 3109601
Novartis Investigative Site
Jerusalem, 9112001
Novartis Investigative Site
Ramat Gan, 5265601
Mexico3 sites
Novartis Investigative Site
Guadalajara, Jalisco, 44100
Novartis Investigative Site
León, Guanajuato, 37178
Novartis Investigative Site
Mexico City, Mexico City, 14080
Sweden3 sites
Novartis Investigative Site
Gothenburg, SE-413 45
Novartis Investigative Site
Lund, 221 85
Novartis Investigative Site
Stockholm, SE 171 76
Belgium2 sites
Novartis Investigative Site
Brussels, 1090
Novartis Investigative Site
Brussels, 1200
Bulgaria2 sites
Novartis Investigative Site
Plovdiv, 4004
Novartis Investigative Site
Sofia, 1303
Greece2 sites
Novartis Investigative Site
Athens, 115 27
Novartis Investigative Site
Athens, 18547
Netherlands2 sites
Novartis Investigative Site
Amersfroort, 3818 ES
Novartis Investigative Site
Leiden, South Holland, 2333
Poland2 sites
Novartis Investigative Site
Gdansk, 80 952
Novartis Investigative Site
Warsaw, 02 781
Portugal2 sites
Novartis Investigative Site
Lisbon, 1099 023
Novartis Investigative Site
Porto, 4200-072
Switzerland2 sites
Novartis Investigative Site
Aarau, Canton of Aargau, 5001
Novartis Investigative Site
Zurich, 8091
Thailand2 sites
Novartis Investigative Site
Bangkok, 10330
Novartis Investigative Site
Songkhla, Hat Yai, 90110
About this study
Official title: A Randomized, Double-blind, Placebo-controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib Versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
The purpose of this study was to evaluate safety and efficacy of the combination of an anti-PD-1 antibody (PDR001), a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in patients with BRAF V600 mutant, unresectable and metastatic melanoma.
Read the detailed description
This study was designed as a phase III, multi-center study consisting of 3 parts:
- Part 1: Safety run-in part The safety run-in part aimed to determine the recommended regimen of PDR001 in combination with dabrafenib and trametinib for previously untreated patients with BRAF V600 mutant unresectable or metastatic melanoma (stage IIIC/IV). Spartalizumab was administered at a starting dose level (DL1) of 400 mg every 4 weeks (Q4W), along with fixed doses of dabrafenib (150 mg twice daily) and trametinib (2 mg once daily). The RP3R for Part 3 was determined using the Bayesian Logistic Regression Model (BLRM) with escalation with overdose control (EWOC) criteria.
- Part 2: Biomarker cohort Part 2 was run to explore changes in the immune microenvironment and biomarker modulations upon treatment with the combination of dabrafenib, trametinib and PDR001. Part 2 started when the fourth subject in dose level 1 (DL1) of Part 1 completed approximately 4 weeks of study treatment, and fewer than 3 dose-limiting toxicities (DLTs) were observed. Participants in Part 2 received PDR001 (spartalizumab) at a dosage of 400 mg Q4W, in combination with dabrafenib (150 mg BID) and trametinib (2 mg QD).
- Part 3: Double-blind, randomized, placebo-controlled part Part 3 was comparing the efficacy and safety of spartalizumab in combination with dabrafenib and trametinib to placebo in combination with dabrafenib and trametinib. Part 3 was initiated after determining the RP3R for the combination of spartalizumab with dabrafenib and trametinib in Part 1. Subjects were randomized in a 1:1 ratio to receive either the RP3R dose of spartalizumab identified in Part 1 or placebo, along with dabrafenib (150 mg BID) and trametinib (2 mg QD).
For all parts of the study, the treatment continued until the subject experiences any of the following events: disease progression according to RECIST 1.1 as determined by the Investigator, unacceptable toxicity, initiation of a new anti-neoplastic therapy, pregnancy, withdrawal of consent, physician's decision, loss to follow-up, death, or termination of the study by the Sponsor. Safety evaluations are conducted for all subjects for up to 150 days after the last dose of spartalizumab/placebo (safety follow-up period).
Subjects who discontinued study treatment without disease progression as per RECIST 1.1 continued with tumor assessments according to the protocol until documented disease progression, withdrawal of consent, loss to follow-up, or death, regardless of the initiation of new anti-neoplastic therapy (efficacy follow-up period).
Subjects entered the survival follow-up period after completing the safety follow-up period or experiencing disease progression as per RECIST 1.1 or response criteria for immunotherapy, whichever period is longer (survival follow-up period).
- Conditions
- Melanoma
- Being tested
- Spartalizumab, Placebo, Dabrafenib, Trametinib
- Keywords
- Spartalizumab (PDR001), dabrafenib, trametinib, melanoma, immunotherapy, PD 1 inhibitor, anti PD1, PD-1, anti-PD-1, combination treatment, malignant skin cancer, skin cancer, BRAF V600, unresectable BRAF V600 mutated melanoma, metastatic BRAF V600 mutated melanoma
- Medical subject headings
- Melanoma, Skin Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SpartalizumabBiological
Also called PDR001
Spartalizumab powder for solution is used in Part 1 and Part 2, and as concentrate for solution for infusion for Part 3. Spartalizumab is administered via intravenous infusion over 30 minutes once every 4 weeks
PlaceboOther
Placebo is administered via intravenous infusion over 30 minutes once every 4 weeks
DabrafenibDrug
Dabrafenib 150 mg capsules BID is administered orally for Days 1-28 of a 28-day cycle, in fasting conditions.
TrametinibDrug
Trametinib 2 mg tablets QD is administered orally for Days 1-28 of a 28-day cycle, in fasting conditions
| Study group | Role | What they receive |
|---|---|---|
| Part 1: Safety run-in Cohort | Experimental | In Part 1, participants are treated at different dose levels to determine the recommended Phase 3 regimen of spartalizumab in combination with dabrafenib and trametinib. The starting dose of spartalizumab is 400 mg Q4W in combination with the approved dose of dabrafenib (150 mg BID) and trametinib (2 mg QD). Receives: Biological: Spartalizumab; Drug: Dabrafenib; Drug: Trametinib |
| Part 2: Biomarker cohort | Experimental | In Part 2, participants are treated with spartalizumab 400 mg Q4W in combination with the approved dose of dabrafenib (150 mg BID) and trametinib (2 mg QD). Receives: Biological: Spartalizumab; Drug: Dabrafenib; Drug: Trametinib |
| Part 3- Arm 1: Spartalizumab in combination with dabrafenib and trametinib | Experimental | In Part 3, participants are randomized to receive spartalizumab at the RP3R identified in Part 1 (400 mg Q4W) in combination with approved dose of dabrafenib (150 mg BID) and trametinib (2 mg QD) Receives: Biological: Spartalizumab; Drug: Dabrafenib; Drug: Trametinib |
| Part 3- Arm 2: Placebo in combination with dabrafenib and trametinib | Placebo comparator | In Part 3, participants are randomized to receive matching placebo in combination with the approved dose of dabrafenib (150 mg BID) and trametinib (2 mg QD) Receives: Other: Placebo; Drug: Dabrafenib; Drug: Trametinib |
What is being measured
The primary outcome is the main question the study is designed to answer.
Safety Run-In (Part 1): Number of Participants With Dose Limiting Toxicities (DLTs)
DLT was defined as an adverse event or abnormal laboratory value that was unrelated to disease, disease progression, inter-current illness, or concomitant medications and occured within 8 weeks of treatment with spartalizumab in combination with dabrafenib and trametinib. The DLT criteria included Grade 4 hematological adverse events, Grade 4 bilirubin elevation, specific gastrointestinal adverse events, symptomatic serum amylase or lipase elevation, Grade 3 or higher hypertension, Grade 3 or higher cardiac events, Grade 2 or higher pneumonitis, Grade 3 or higher immune-related toxicities, infusion-related reactions, other clinically significant adverse events, and toxicities leading to a dosing delay of over 12 weeks. NCI CTCAE v4.03 was used for grading DLTs
Measured: Up to 8 weeks (Part 1)
Biomarker Cohort (Part 2): Change From Baseline in Programmed Cell Death-ligand 1 (PD-L1) Expression Upon Treatment With Spartalizumab in Combination With Dabrafenib and Trametinib
Change from baseline in PD-L1 expression (as determined by immunohistochemistry in tissue samples) upon treatment with spartalizumab in combination with dabrafenib and trametinib in participants from Part 2
Measured: Baseline, Cycle 1 Day 15 and Cycle 3 Day 1 (Part 2). Each cycle is 28 days
Biomarker Cohort (Part 2): Change From Baseline in CD8+ Cells Upon Treatment With Spartalizumab in Combination With Dabrafenib and Trametinib
Change from baseline in CD8+ cells (as determined by flow cytometry in blood samples) upon treatment with spartalizumab in combination with dabrafenib and trametinib in participants from Part 2
Measured: Baseline, Cycle 1 Day 15 and Cycle 3 Day 1 (Part 2). Each cycle is 28 days
Randomized (Part 3): Progression-Free Survival (PFS) as Per Investigator's Assessment by RECIST 1.1
Progression-free survival was defined as the time from the date of first dose to the date of the first documented radiological progression per investigator's assessment according to RECIST 1.1 or death due to any cause. The distribution of PFS was estimated using the Kaplan-Meier (KM) method. If a patient had not had an event at the time of data cut-off, progression-free survival was censored at the date of last adequate tumor assessment.
Measured: Up to disease progression or death due to any cause, whichever occurs first, assessed up to 2.8 years (Part 3)
Secondary outcomes (20)
Overall Survival (OS)
Overall survival was defined as the time from date of randomization to date of death due to any cause
Measured: Up to death due to any cause, assessed up to approximately 7 years
Overall Response Rate (ORR) as Per Investigator's Assessment by RECIST 1.1
ORR was defined as the percentage of subjects with confirmed best overall response of complete response (CR) or partial response (PR), as per investigator's assessment by RECIST 1.1. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to <10 mm PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters
Measured: Part 1: Up to 3.3 years. Part 2: Up to 3 years. Part 3: Up to 2.8 years
Duration of Response (DOR) as Per Investigator's Assessment by RECIST 1.1
DOR was defined as the time from first documented response of CR or PR to date of first documented progression or death, according to RECIST 1.1 criteria. The distribution of DOR was estimated using the KM method. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to <10 mm PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters
Measured: From first documented response to date of first documented progression or death, up to 3.3 years (Part 1), 3 years (Part 2) and 2.8 years (Part 3)
Disease Control Rate (DCR) as Per Investigator's Assessment by RECIST 1.1
DCR was defined as the percentage of participants with CR or PR or subjects with stable disease (SD) lasting for a duration of at least 24 weeks as per local review according to RECIST 1.1 criteria. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to <10 mm PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease.
Measured: Part 1: Up to 3.3 years. Part 2: Up to 3 years. Part 3: Up to 2.8 year
Randomized (Part 3): Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) C30- Global Health Status Scores
The EORTC QLQ-C30 was a 30-item questionnaire that patients complete, consisting of both multi-item scales and single-item measures. It included five functional scales, three symptom scales, six single items, and a Global Health Status/Quality of Life (GHS/QoL) scale. The GHS/QoL scale had seven possible response scores ranging from 1 (very poor) to 7 (excellent), which were averaged and transformed to a 0-100 scale. A higher score on this scale indicated a better quality of life. The change from baseline in GHS/QoL scores was calculated. A positive change from baseline indicated improvement in the patient's quality of life.
Measured: From baseline to 60 days post progression, assessed up to 2.8 years (Part 3)
Randomized (Part 3): Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) C30- Physical Functioning Scale Scores
The EORTC QLQ-C30 was a patient completed 30 item questionnaire that was composed of both multi-item scales and single-item measures. These included five functional scales, three symptom scales, six single items and a global health status/QoL scale. The EORTC QLQ-C30 physical functioning scale measured a patient's ability to carry out daily activities and tasks requiring physical exertion. It consisted of five questions asking patients to rate their level of physical functioning, with response options ranging from 1="not at all" to 4="very much". The scores for each item were summed and transformed to a 0 to 100 scale, with higher scores indicating better physical functioning. The change from baseline in physical functioning scale scores was calculated. A positive change from baseline indicated improvement in physical functioning.
Measured: From baseline to 60 days post progression, assessed up to 2.8 years (Part 3)
Randomized (Part 3): Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) C30- Pain Symptom Scale Scores
The EORTC QLQ-C30 was a patient completed 30 item questionnaire that was composed of both multi-item scales and single-item measures. These included five functional scales, three symptom scales, six single items and a global health status/QoL scale. The EORTC QLQ-C30 pain symptom scale was one of the symptom scales in the questionnaire, which measured the severity of pain experienced by the patient. The pain symptom scale consisted of two items, one measuring the severity of pain and the other measuring the use of painkillers. The items were rated on a 4-point scale ranging from 1="not at all" to 4="very much". The scores for each item were summed and transformed to a 0 to 100 scale, with higher scores indicating more severe pain. The change from baseline in pain symptom scale scores was calculated. A negative change from baseline indicated improvement.
Measured: From baseline to 60 days post progression, assessed up to 2.8 years (Part 3)
Randomized (Part 3): Time to 10 Point Definitive Deterioration in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) C30- Global Health Status
The EORTC QLQ-C30 was a patient completed 30 item questionnaire that was composed of both multi-item scales and single-item measures. These included five functional scales, three symptom scales, six single items and a global health status/QoL scale. The GHS/QoL scale had seven possible response scores ranging from 1 (very poor) to 7 (excellent), which were averaged and transformed to a 0-100 scale. A higher score on this scale indicated a better quality of life. The time to definitive 10 point deterioration is defined as the time from the date of randomization to the date of event, which is defined as at least 10 points relative to baseline worsening of the GHS/QoL score or death due to any cause. If a subject had not had an event, the time to deterioration was censored at the date of the last adequate assessment. The distribution was estimated using KM method.
Measured: From baseline to date of at least 10 points relative to baseline worsening of the global health status score or death due to any cause, up to 2.8 years (Part 3)
Randomized (Part 3): Change From Baseline in Function Assessment Cancer Therapy-melanoma (FACT-M) Melanoma Subscale Score
The Functional Assessment of Cancer Therapy-Melanoma (FACT-M) quality of life questionnaire was composed of the FACT-General (FACT-G) plus the Melanoma Subscale and the Melanoma Surgery Subscale, which complemented the general scale with items specific to quality of life (QoL) in melanoma. The Melanoma Subscale of FACT-M included 16 questions, with response options of 0= "Not at all", 1= "a little bit", 2= "somewhat", 3= "quite a bit" and 4= "very much". The FACT-M melanoma subscale score ranged from 0 to 64, with higher scores indicating a higher quality of life in relation to melanoma. The change from baseline in melanoma subscale scores was calculated. A positive change from baseline indicated improvement.
Measured: From baseline to 60 days post progression, assessed up to 2.8 years (Part 3)
Randomized (Part 3): Change From Baseline in EuroQoL 5-level Instrument (EQ-5D-5L)- Visual Analog Scale (VAS) Score
The EQ-5D-5L is a standardized questionnaire used to assess health-related quality of life, and it includes a Visual Analog Scale (VAS). The VAS score is obtained by asking the individual to rate their current health status on a scale from 0 to 100, where 0 represents the worst possible health state and 100 represents the best possible health state. The change from baseline in EQ-5D-5L VAS score was calculated. A positive change from baseline indicates improvement in the health status.
Measured: From baseline to 60 days post progression, assessed up to 2.8 years (Part 3)
Randomized (Part 3): PFS as Per Investigator's Assessment by RECIST 1.1 by PD-L1 Expression
PFS was defined as the time from the date of first dose to the date of the first documented radiological progression as per investigator's assessment using RECIST 1.1 response criteria or death due to any cause. The distribution of PFS was estimated using the KM method. If a patient had not had an event at the time of data cut-off, progression-free survival was censored at the date of last adequate tumor assessment. PFS analysis was performed by PD-L1 status (positive, negative) where a positive status was defined as having ≥ 1% expression and a negative status was defined as having < 1% expression.
Measured: Up to disease progression or death due to any cause, up to 2.8 years (Part 3)
Randomized (Part 3): OS by PD-L1 Expression
Overall survival was defined as the time from date of randomization to date of death due to any cause. OS analysis was performed by PD-L1 subgroup (positive, negative) where a positive status was defined as having ≥ 1% expression and a negative status was defined as having < 1% expression.
Measured: Up to death due to any cause, assessed up to approximately 7 years
Spartalizumab Anti-drug Antibody (ADA) Prevalence at Baseline
Spartalizumab ADA prevalence at baseline was calculated as the percentage of participants who had an spartalizumab ADA positive result at baseline.
Measured: Baseline
Spartalizumab ADA Incidence
Spartalizumab ADA incidence was calculated as the percentage of participants who were treatment-induced spartalizumab ADA positive (post-baseline ADA positive with ADA-negative sample at baseline) and treatment-boosted spartalizumab ADA positive (post-baseline ADA positive with titer that is at least the fold titer change greater than the ADA-positive baseline titer)
Measured: Throughout study until 150 days after the last dose of spartalizumab, up to 3.3 years (Part 1), 3 years (Part 2) and 2.8 years (Part 3).
Trough Concentration (Ctrough) for Spartalizumab
Ctrough for spartalizumab refers to the serum concentration of spartalizumab immediately prior to the administration of a dose of spartalizumab on Day 1 of Cycle 2 and later cycles.
Measured: Pre-infusion on Day 1 of each Cycle starting from Cycle 2, up to 3.3 years (Part 1), 3 years (Part 2) and 2.8 years (Part 3). Cycle=28 days
Pre-dose Plasma Concentration for Dabrafenib
Plasma concentration of dabrafenib immediately prior to the administration of a dose of dabrafenib.
Measured: Pre-infusion on Day 1 of every cycle from Cycle 2 to 12, and then every 6 cycles from Cycle 18 to 36, up to 3.3 years (Part 1), 3 years (Part 2) and 2.8 years (Part 3). Cycle=28 days
Pre-dose Plasma Concentration for Trametinib
Plasma concentration of trametinib immediately prior to the administration of a dose of trametinib.
Measured: Pre-infusion on Day 1 of every cycle from Cycle 2 to 12, and then every 6 cycles from Cycle 18 to 36, up to 3.3 years (Part 1), 3 years (Part 2) and 2.8 years (Part 3). Cycle=28 days
Number of Participants With Dose Interruptions
Number of participants with dose interruptions for spartalizumab, dabrafenib and trametinib
Measured: From baseline to end of treatment, assessed up to approximately 7 years
Number of Participants With Dose Reductions
Number of patients with dose reductions for spartalizumab, dabrafenib and trametinib
Measured: From baseline to end of treatment, assessed up to approximately 7 years
Relative Dose Intensity
Relative dose intensity for spartalizumab, dabrafenib and trametinib computed as the ratio (expressed as percentage) of dose intensity and planned dose intensity:
- Spartalizumab (PDR001) = [Dose intensity (mg/4W) / planned dose intensity (mg/4W)]*100.
- Trametinib and Dabrafenib = [Dose intensity (mg/day) / planned dose intensity (mg/day)]*100.
Measured: From baseline to end of treatment, assessed up to approximately 7 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Nov 2016 (estimated)
- Study start17 Feb 2017
- Primary completion11 Aug 2020
- Study completion21 Aug 2024
Why it stopped: Sponsor decision
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for MelanomaStudies of the same condition, open and under way.
- More trials run by Novartis PharmaceuticalsThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 568 participants (actual)
Sponsor and investigators
- Lead sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Novartis Pharmaceuticals, Study director, Novartis Pharmaceuticals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02967692
- Sponsor's protocol ID
- CPDR001F2301
- Other IDs
- 2016-002794-35, 2016
- Acronym
- COMBI-i
- Status last verified
- Sep 2025
- First submitted
- 16 Nov 2016
- Last updated
- 18 Sep 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Publications
Ribas A, Robert C, Schadendorf D, Long GV, Tawbi H, Flaherty K, Ascierto PA, Nathan P, Rutkowski P, Leonov OV, Lorigan P, Prey S, Saponara M, Arance A, Gaudy-Marqueste C, Stroyakovskiy D, Lebbe C, Maio M, Del Vecchio M, Boghikian PS, Gutzmer R, Depenni R, Miskic M, Russo M, Dummer R. COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma. J Clin Oncol. 2026 Aug 12:JCO2600528. doi: 10.1200/JCO-26-00528. Online ahead of print.
PubMed 42585631Tawbi HA, Robert C, Brase JC, Gusenleitner D, Gasal E, Garrett J, Savchenko A, Gorgun G, Flaherty KT, Ribas A, Dummer R, Schadendorf D, Long GV, Nathan PD, Ascierto PA. Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i). J Immunother Cancer. 2022 Jun;10(6):e004226. doi: 10.1136/jitc-2021-004226.
PubMed 35728875Dummer R, Long GV, Robert C, Tawbi HA, Flaherty KT, Ascierto PA, Nathan PD, Rutkowski P, Leonov O, Dutriaux C, Mandala M, Lorigan P, Ferrucci PF, Grob JJ, Meyer N, Gogas H, Stroyakovskiy D, Arance A, Brase JC, Green S, Haas T, Masood A, Gasal E, Ribas A, Schadendorf D. Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma. J Clin Oncol. 2022 May 1;40(13):1428-1438. doi: 10.1200/JCO.21.01601. Epub 2022 Jan 14.
PubMed 35030011Dummer R, Lebbe C, Atkinson V, Mandala M, Nathan PD, Arance A, Richtig E, Yamazaki N, Robert C, Schadendorf D, Tawbi HA, Ascierto PA, Ribas A, Flaherty KT, Pakhle N, Campbell CD, Gusenleitner D, Masood A, Brase JC, Gasal E, Long GV. Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. Nat Med. 2020 Oct;26(10):1557-1563. doi: 10.1038/s41591-020-1082-2. Epub 2020 Oct 5.
PubMed 33020648
Study at a glance
From the registry record, last updated by the sponsor on 18 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-blind, Placebo-controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib Versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
- ClinicalTrials.gov ID
- NCT02967692
- Acronym / sponsor ID
- COMBI-i / CPDR001F2301
- Conditions
- Melanoma
- Keywords
- Spartalizumab (PDR001), dabrafenib, trametinib, melanoma, immunotherapy, PD 1 inhibitor, anti PD1, PD-1
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Sponsor decision
- Enrolment
- 568 participants (actual)
- Lead sponsor
- Novartis PharmaceuticalsIndustry (pharma, biotech, devices)
- Study start
- 17 Feb 2017 (actual)
- Primary completion
- 11 Aug 2020 (actual)
- Study completion
- 21 Aug 2024 (actual)
- First posted
- 18 Nov 2016 (estimated)
- Results
- Posted 24 Jul 2023
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study was to evaluate safety and efficacy of the combination of an anti-PD-1 antibody (PDR001), a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in patients with BRAF V600 mutant, unresectable and metastatic melanoma.
Detailed description
This study was designed as a phase III, multi-center study consisting of 3 parts:
- Part 1: Safety run-in part The safety run-in part aimed to determine the recommended regimen of PDR001 in combination with dabrafenib and trametinib for previously untreated patients with BRAF V600 mutant unresectable or metastatic melanoma (stage IIIC/IV). Spartalizumab was administered at a starting dose level (DL1) of 400 mg every 4 weeks (Q4W), along with fixed doses of dabrafenib (150 mg twice daily) and trametinib (2 mg once daily). The RP3R for Part 3 was determined using the Bayesian Logistic Regression Model (BLRM) with escalation with overdose control (EWOC) criteria.
- Part 2: Biomarker cohort Part 2 was run to explore changes in the immune microenvironment and biomarker modulations upon treatment with the combination of dabrafenib, trametinib and PDR001. Part 2 started when the fourth subject in dose level 1 (DL1) of Part 1 completed approximately 4 weeks of study treatment, and fewer than 3 dose-limiting toxicities (DLTs) were observed. Participants in Part 2 received PDR001 (spartalizumab) at a dosage of 400 mg Q4W, in combination with dabrafenib (150 mg BID) and trametinib (2 mg QD).
- Part 3: Double-blind, randomized, placebo-controlled part Part 3 was comparing the efficacy and safety of spartalizumab in combination with dabrafenib and trametinib to placebo in combination with dabrafenib and trametinib. Part 3 was initiated after determining the RP3R for the combination of spartalizumab with dabrafenib and trametinib in Part 1. Subjects were randomized in a 1:1 ratio to receive either the RP3R dose of spartalizumab identified in Part 1 or placebo, along with dabrafenib (150 mg BID) and trametinib (2 mg QD).
For all parts of the study, the treatment continued until the subject experiences any of the following events: disease progression according to RECIST 1.1 as determined by the Investigator, unacceptable toxicity, initiation of a new anti-neoplastic therapy, pregnancy, withdrawal of consent, physician's decision, loss to follow-up, death, or termination of the study by the Sponsor. Safety evaluations are conducted for all subjects for up to 150 days after the last dose of spartalizumab/placebo (safety follow-up period).
Subjects who discontinued study treatment without disease progression as per RECIST 1.1 continued with tumor assessments according to the protocol until documented disease progression, withdrawal of consent, loss to follow-up, or death, regardless of the initiation of new anti-neoplastic therapy (efficacy follow-up period).
Subjects entered the survival follow-up period after completing the safety follow-up period or experiencing disease progression as per RECIST 1.1 or response criteria for immunotherapy, whichever period is longer (survival follow-up period).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Part 1: Safety run-in Cohort | Experimental | Biological: Spartalizumab, Drug: Dabrafenib, Drug: TrametinibIn Part 1, participants are treated at different dose levels to determine the recommended Phase 3 regimen of spartalizumab in combination with dabrafenib and trametinib. The starting dose of spartalizumab is 400 mg Q4W in combination with the approved dose of dabrafenib (150 mg BID) and trametinib (2 mg QD). |
| Part 2: Biomarker cohort | Experimental | Biological: Spartalizumab, Drug: Dabrafenib, Drug: TrametinibIn Part 2, participants are treated with spartalizumab 400 mg Q4W in combination with the approved dose of dabrafenib (150 mg BID) and trametinib (2 mg QD). |
| Part 3- Arm 1: Spartalizumab in combination with dabrafenib and trametinib | Experimental | Biological: Spartalizumab, Drug: Dabrafenib, Drug: TrametinibIn Part 3, participants are randomized to receive spartalizumab at the RP3R identified in Part 1 (400 mg Q4W) in combination with approved dose of dabrafenib (150 mg BID) and trametinib (2 mg QD) |
| Part 3- Arm 2: Placebo in combination with dabrafenib and trametinib | Placebo comparator | Other: Placebo, Drug: Dabrafenib, Drug: TrametinibIn Part 3, participants are randomized to receive matching placebo in combination with the approved dose of dabrafenib (150 mg BID) and trametinib (2 mg QD) |
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (13 listed)
- Histologically confirmed, unresectable or metastatic melanoma with BRAF V600 mutation
- Aspartate transaminase (AST) < 2.5× ULN and Alanine transaminase (ALT) < 2.5× ULN
- Measurable disease according to RECIST 1.1
- ECOG performance status ≤ 1
- Part 2: Biomarker cohort
Key exclusion criteria (15 listed)
- Part 1: Safety run-in
- Subjects with uveal or mucosal melanoma
- Any history of CNS metastases
- Prior systemic anti-cancer treatment for unresectable or metastatic melanoma
- Neoadjuvant and/or adjuvant therapy for melanoma completed less than 6 months prior to enrollmen
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SpartalizumabAlso: PDR001Spartalizumab powder for solution is used in Part 1 and Part 2, and as concentrate for solution for infusion for Part 3. Spartalizumab is administered via intravenous infusion over 30 minutes once every 4 weeks | Biological | Part 1: Safety run-in Cohort, Part 2: Biomarker cohort, Part 3- Arm 1: Spartalizumab in combination with dabrafenib and trametinib |
| PlaceboPlacebo is administered via intravenous infusion over 30 minutes once every 4 weeks | Other | Part 3- Arm 2: Placebo in combination with dabrafenib and trametinib |
| DabrafenibDabrafenib 150 mg capsules BID is administered orally for Days 1-28 of a 28-day cycle, in fasting conditions. | Drug | Part 1: Safety run-in Cohort, Part 2: Biomarker cohort, Part 3- Arm 1: Spartalizumab in combination with dabrafenib and trametinib, Part 3- Arm 2: Placebo in combination with dabrafenib and trametinib |
| TrametinibTrametinib 2 mg tablets QD is administered orally for Days 1-28 of a 28-day cycle, in fasting conditions | Drug | Part 1: Safety run-in Cohort, Part 2: Biomarker cohort, Part 3- Arm 1: Spartalizumab in combination with dabrafenib and trametinib, Part 3- Arm 2: Placebo in combination with dabrafenib and trametinib |
Primary outcome
Safety Run-In (Part 1): Number of Participants With Dose Limiting Toxicities (DLTs)
Time frame: Up to 8 weeks (Part 1)
DLT was defined as an adverse event or abnormal laboratory value that was unrelated to disease, disease progression, inter-current illness, or concomitant medications and occured within 8 weeks of treatment with spartalizumab in combination with dabrafenib and trametinib. The DLT criteria included Grade 4 hematological adverse events, Grade 4 bilirubin elevation, specific gastrointestinal adverse events, symptomatic serum amylase or lipase elevation, Grade 3 or higher hypertension, Grade 3 or higher cardiac events, Grade 2 or higher pneumonitis, Grade 3 or higher immune-related toxicities, infusion-related reactions, other clinically significant adverse events, and toxicities leading to a dosing delay of over 12 weeks. NCI CTCAE v4.03 was used for grading DLTs
Biomarker Cohort (Part 2): Change From Baseline in Programmed Cell Death-ligand 1 (PD-L1) Expression Upon Treatment With Spartalizumab in Combination With Dabrafenib and Trametinib
Time frame: Baseline, Cycle 1 Day 15 and Cycle 3 Day 1 (Part 2). Each cycle is 28 days
Change from baseline in PD-L1 expression (as determined by immunohistochemistry in tissue samples) upon treatment with spartalizumab in combination with dabrafenib and trametinib in participants from Part 2
Biomarker Cohort (Part 2): Change From Baseline in CD8+ Cells Upon Treatment With Spartalizumab in Combination With Dabrafenib and Trametinib
Time frame: Baseline, Cycle 1 Day 15 and Cycle 3 Day 1 (Part 2). Each cycle is 28 days
Change from baseline in CD8+ cells (as determined by flow cytometry in blood samples) upon treatment with spartalizumab in combination with dabrafenib and trametinib in participants from Part 2
Randomized (Part 3): Progression-Free Survival (PFS) as Per Investigator's Assessment by RECIST 1.1
Time frame: Up to disease progression or death due to any cause, whichever occurs first, assessed up to 2.8 years (Part 3)
Progression-free survival was defined as the time from the date of first dose to the date of the first documented radiological progression per investigator's assessment according to RECIST 1.1 or death due to any cause. The distribution of PFS was estimated using the Kaplan-Meier (KM) method. If a patient had not had an event at the time of data cut-off, progression-free survival was censored at the date of last adequate tumor assessment.
20 secondary outcomes
Overall Survival (OS)
Time frame: Up to death due to any cause, assessed up to approximately 7 years
Overall Response Rate (ORR) as Per Investigator's Assessment by RECIST 1.1
Time frame: Part 1: Up to 3.3 years. Part 2: Up to 3 years. Part 3: Up to 2.8 years
Duration of Response (DOR) as Per Investigator's Assessment by RECIST 1.1
Time frame: From first documented response to date of first documented progression or death, up to 3.3 years (Part 1), 3 years (Part 2) and 2.8 years (Part 3)
Disease Control Rate (DCR) as Per Investigator's Assessment by RECIST 1.1
Time frame: Part 1: Up to 3.3 years. Part 2: Up to 3 years. Part 3: Up to 2.8 year
Randomized (Part 3): Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) C30- Global Health Status Scores
Time frame: From baseline to 60 days post progression, assessed up to 2.8 years (Part 3)
Randomized (Part 3): Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) C30- Physical Functioning Scale Scores
Time frame: From baseline to 60 days post progression, assessed up to 2.8 years (Part 3)
Randomized (Part 3): Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) C30- Pain Symptom Scale Scores
Time frame: From baseline to 60 days post progression, assessed up to 2.8 years (Part 3)
Randomized (Part 3): Time to 10 Point Definitive Deterioration in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) C30- Global Health Status
Time frame: From baseline to date of at least 10 points relative to baseline worsening of the global health status score or death due to any cause, up to 2.8 years (Part 3)
Randomized (Part 3): Change From Baseline in Function Assessment Cancer Therapy-melanoma (FACT-M) Melanoma Subscale Score
Time frame: From baseline to 60 days post progression, assessed up to 2.8 years (Part 3)
Randomized (Part 3): Change From Baseline in EuroQoL 5-level Instrument (EQ-5D-5L)- Visual Analog Scale (VAS) Score
Time frame: From baseline to 60 days post progression, assessed up to 2.8 years (Part 3)
Randomized (Part 3): PFS as Per Investigator's Assessment by RECIST 1.1 by PD-L1 Expression
Time frame: Up to disease progression or death due to any cause, up to 2.8 years (Part 3)
Randomized (Part 3): OS by PD-L1 Expression
Time frame: Up to death due to any cause, assessed up to approximately 7 years
Spartalizumab Anti-drug Antibody (ADA) Prevalence at Baseline
Time frame: Baseline
Spartalizumab ADA Incidence
Time frame: Throughout study until 150 days after the last dose of spartalizumab, up to 3.3 years (Part 1), 3 years (Part 2) and 2.8 years (Part 3).
Trough Concentration (Ctrough) for Spartalizumab
Time frame: Pre-infusion on Day 1 of each Cycle starting from Cycle 2, up to 3.3 years (Part 1), 3 years (Part 2) and 2.8 years (Part 3). Cycle=28 days
Pre-dose Plasma Concentration for Dabrafenib
Time frame: Pre-infusion on Day 1 of every cycle from Cycle 2 to 12, and then every 6 cycles from Cycle 18 to 36, up to 3.3 years (Part 1), 3 years (Part 2) and 2.8 years (Part 3). Cycle=28 days
Pre-dose Plasma Concentration for Trametinib
Time frame: Pre-infusion on Day 1 of every cycle from Cycle 2 to 12, and then every 6 cycles from Cycle 18 to 36, up to 3.3 years (Part 1), 3 years (Part 2) and 2.8 years (Part 3). Cycle=28 days
Number of Participants With Dose Interruptions
Time frame: From baseline to end of treatment, assessed up to approximately 7 years
Number of Participants With Dose Reductions
Time frame: From baseline to end of treatment, assessed up to approximately 7 years
Relative Dose Intensity
Time frame: From baseline to end of treatment, assessed up to approximately 7 years
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Sep 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 42585631Ribas A, Robert C, Schadendorf D, Long GV, Tawbi H, Flaherty K, Ascierto PA, Nathan P, Rutkowski P, Leonov OV, Lorigan P, Prey S, Saponara M, Arance A, Gaudy-Marqueste C, Stroyakovskiy D, Lebbe C, Maio M, Del Vecchio M, Boghikian PS, Gutzmer R, Depenni R, Miskic M, Russo M, Dummer R. COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma. J Clin Oncol. 2026 Aug 12:JCO2600528. doi: 10.1200/JCO-26-00528. Online ahead of print.
- Derived from this study: PubMed 35728875Tawbi HA, Robert C, Brase JC, Gusenleitner D, Gasal E, Garrett J, Savchenko A, Gorgun G, Flaherty KT, Ribas A, Dummer R, Schadendorf D, Long GV, Nathan PD, Ascierto PA. Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i). J Immunother Cancer. 2022 Jun;10(6):e004226. doi: 10.1136/jitc-2021-004226.
- Derived from this study: PubMed 35030011Dummer R, Long GV, Robert C, Tawbi HA, Flaherty KT, Ascierto PA, Nathan PD, Rutkowski P, Leonov O, Dutriaux C, Mandala M, Lorigan P, Ferrucci PF, Grob JJ, Meyer N, Gogas H, Stroyakovskiy D, Arance A, Brase JC, Green S, Haas T, Masood A, Gasal E, Ribas A, Schadendorf D. Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma. J Clin Oncol. 2022 May 1;40(13):1428-1438. doi: 10.1200/JCO.21.01601. Epub 2022 Jan 14.
- Derived from this study: PubMed 33020648Dummer R, Lebbe C, Atkinson V, Mandala M, Nathan PD, Arance A, Richtig E, Yamazaki N, Robert C, Schadendorf D, Tawbi HA, Ascierto PA, Ribas A, Flaherty KT, Pakhle N, Campbell CD, Gusenleitner D, Masood A, Brase JC, Gasal E, Long GV. Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. Nat Med. 2020 Oct;26(10):1557-1563. doi: 10.1038/s41591-020-1082-2. Epub 2020 Oct 5.
- Individual participant dataSharing planned: Yes. Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Related trials for Melanoma
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 1
IL-17 Blockade to Decrease irAEs (REPLAY)
Metastatic Melanoma
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 1
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
Melanoma
Active, not recruitingPhase 1/2
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
Melanoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Novartis Pharmaceuticals study director
Novartis Pharmaceuticals
179 sites in 29 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Spartalizumab, Dabrafenib and Trametinib in people with Melanoma, run by Novartis Pharmaceuticals at 179 sites in 29 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 18 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 179 sites in France, Germany, Italy, Spain, United States and 24 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 24 Jul 2023). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Safety Run-In (Part 1): Number of Participants With Dose Limiting Toxicities (DLTs) (time frame: Up to 8 weeks (Part 1)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02967692, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Sep 2025.